MELI up +0.79% percent Today $MELI High is at 136.66 and

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 2:23 PM

MELI up +0.79% percent Today $MELI High is at 136.66 and the Low 134.07 with current volume of 98,103.

Recent News posted below.

Mercadolibre Inc MELI other info.
http://investorshangout.com/Mercadolibre-MELI-54734/

MELI Mercadolibre Inc Recent Headline News

MercadoLibre Earnings Hindsight: Up 17.0% in Last 11 Days (MELI)
Comtex SmarTrend(R) - 1 hr 13 mins ago
When MercadoLibre (NASDAQ:MELI) reported earnings 11 days ago on October 30th, 2014, analysts, on average, expected the company to report earnings of $0.66 on sales of $129.6 million. MercadoLibre actually reported earnings of $0.76 per share on sales of $147.9 million, beating EPS estimates by $0.10 and beating revenue estimates by $18.4 million. Since the company's report, shares of MercadoLibre have risen from $115.20 to $134.75, representing a gain of 17.0% in the past 11 days.
MELI: 136.50 (+1.75)

Insider Trading Alert - MELI, CBT And EXXI Traded By Insiders
at The Street - 2 hrs 1 min ago
Stocks with insider trader activity include MELI, CBT and EXXI
EXXI: 7.02 (-0.28), MELI: 136.50 (+1.75), CBT: 46.71 (-0.14)

My Challenges As A Dividend Growth Investor
Integrator - at Seeking Alpha - Fri Nov 07, 4:34PM CST

KO: 42.32 (unch), NKE: 94.87 (+1.09), HSY: 96.55 (+0.12), DIS: 89.65 (-0.35), QSII: 14.51 (-0.05), PEP: 96.79 (-0.01), SBUX: 77.66 (-0.13), JNJ: 108.67 (+0.47), V: 249.00 (-3.43), MJN: 99.15 (+0.76), MCD: 95.09 (-0.01), BP: 41.91 (-0.15), PG: 89.32 (+0.19), MELI: 136.50 (+1.75), FHCO: 4.49 (unch), CSCO: 25.14 (-0.19), MA: 84.78 (-0.02), CL: 68.41 (+0.36)

Does Google Glass Create Blind Spots for Your Vision? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 12:22PM CST
While Google Inc. (GOOGL) has been guaranteeing an increased visual experience with on-the-go, hands-free entree to photos, videos,emails, web-surfing and apps with its ground-breaking Google Glass, a recent study has revealed that it runs the risk of creating blind spots.
BIDU: 246.22 (+9.68), XWES: 5.44 (+0.01), GOOGL: 558.62 (+6.80), MELI: 136.50 (+1.75)

Microsemi Tops Q4 Earnings on High Volume; Favorable View - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 8:20AM CST
Microsemi Corporation's (MSCC) adjusted earnings in the fourth quarter of fiscal 2014 of 56 cents per share exceeded the Zacks Consensus Estimate by 4 cents due to higher volume which resulted in stronger revenues.
ABTL: 10.08 (+0.18), MSCC: 26.90 (+0.43), MELI: 136.50 (+1.75), ZU: 28.71 (+0.21)

Autobytel (ABTL) Jumps: Stock Adds 7.6% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:37AM CST
Autobytel Inc. (ABTL) was a big mover last session, as the company saw its shares rise nearly 8% on the day.
ABTL: 10.08 (+0.18), STMP: 43.15 (+0.23), MELI: 136.50 (+1.75), ZU: 28.71 (+0.21)

Netflix to Enter Australia by 2015, Boosts Overseas Business - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 4:40PM CST
Netflix, Inc. (NFLX) is reportedly set to hit the Australian market in 2015 with the launch of its services.
NFLX: 387.03 (+2.87), ABTL: 10.08 (+0.18), MELI: 136.50 (+1.75), NWS: 14.90 (+0.06)

Mercadolibre (MELI) & FreightCar America (RAIL): Top Momentum Stocks for November 6th - Video Blog
David Bartosiak - Zacks Investment Research - Thu Nov 06, 12:57PM CST
Mercadolibre (MELI) & FreightCar America (RAIL) are this week's top momentum stocks discussed by Momentum Strategist David Bartosiak.
RAIL: 34.07 (+0.71), MELI: 136.50 (+1.75)

Mercadolibre (MELI) Shares March Higher, Can It Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Nov 06, 8:07AM CST
Mercadolibre (MELI) Shares March Higher, Can It Continue?
MELI: 136.50 (+1.75)

MercadoLibre Price Target Hiked; Brazil A Challenge
at Investor's Business Daily - Wed Nov 05, 12:12PM CST
A re-acceleration of growth in Brazil, e-commerce firm MercadoLibre's largest market, would likely trump any macro risks elsewhere in Latin America, says Morgan Stanley, which on Wednesday raised its price target on MercadoLibre stock. Analyst Michel...
AMZN: 304.05 (+4.19), EBAY: 53.77 (+0.26), MELI: 136.50 (+1.75), BABA: 117.64 (+3.08)

Alibaba Group (BABA) Lags Q2 Earnings on High Expenses - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Nov 05, 8:40AM CST
Alibaba Group Holding Limited (BABA) reported second-quarter fiscal 2015 (ended Sep 30, 2014) earnings of 25 cents per share, missing the Zacks Consensus Estimate of 37 cents due to increased investments in mobile, marketing and other new ventures.
ABTL: 10.08 (+0.18), MELI: 136.50 (+1.75), ZU: 28.71 (+0.21), BABA: 117.64 (+3.08)

New App Launch, Quarterly Financial Results, Conference Schedules, and Designer Collection - Research Reports on Yum, Mercadolibre, United Continental, FleetCor and Target
PR Newswire - Wed Nov 05, 7:40AM CST
Today, Analysts Review released its research reports regarding Yum! Brands, Inc. (NYSE: YUM), Mercadolibre, Inc. (NASDAQ: MELI), United Continental Holdings, Inc. (NYSE: UAL), FleetCor Technologies, Inc. (NYSE: FLT) and Target Corp. (NYSE: TGT). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/7702-100free.
TGT: 65.32 (+1.15), FLT: 149.34 (+0.16), MELI: 136.50 (+1.75), UAL: 54.79 (+0.61), YUM: 73.33 (+0.47)

MercadoLibre Rises 18.19% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Oct 31, 4:12PM CDT
MercadoLibre (NASDAQ:MELI) traded in a range yesterday that spanned from a low of $131.06 to a high of $144.23. Yesterday, the shares gained 18.2%, which took the trading range above the 3-day high of $116.00 on volume of 2.9 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
MELI: 136.50 (+1.75)

Strong Q3 report propels shares of MercadoLibre
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 1:40PM CDT

MELI: 136.50 (+1.75)

Why MercadoLibre Inc.'s Shares Skyrocketed
Alex Planes, The Motley Fool - Motley Fool - Fri Oct 31, 12:26PM CDT
This article originally appeared as part of ongoing coverage in our premium Motley Fool Rule Breakers service... we hope you enjoy this complimentary peek! What's happening? Shares of MercadoLibre are trading...
MELI: 136.50 (+1.75)

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 11:47AM CDT

MEP: 14.26 (+0.01), SREV: 4.27 (+0.11), SGMS: 12.57 (+0.18), CDTI: 2.69 (+0.19), NKA: 5.10 (-0.31), WETF: 15.55 (-0.05), EPAY: 25.23 (+0.03), AEGR: 21.57 (-0.01), YOD: 2.88 (+0.01), RM: 12.16 (-0.16), GCAP: 8.93 (-0.09), MGI: 8.36 (-0.05), KGC: 2.35 (-0.15), STAA: 8.89 (-0.06), ADNC: 4.24 (+0.24), GRPN: 7.49 (-0.01), MELI: 136.50 (+1.75), IMPV: 43.09 (+0.56), OPLK: 20.62 (-0.01), CODE: 20.70 (+0.25)

Stocks Surge At Starting Bell; Mylan, Expedia, GoPro Rocket
at Investor's Business Daily - Fri Oct 31, 9:36AM CDT
Stocks sprinted out of the starting gate Friday, with economic news, quarterly reports and international markets all adding lift. The Nasdaq staked out an early lead, up 1.2%, asMylan (MYL), Analog Devices (ADI) and Expedia (EXPE) all opened more...
AMBA: 48.65 (+1.51), GPRO: 76.15 (-2.91), EXPE: 85.91 (+0.80), ADI: 50.28 (+0.04), MYL: 53.87 (+0.76), MELI: 136.50 (+1.75)

Mercadolibre (MELI) Stock Jumps to 11-Month High Today After Third Quarter Earnings Results
at The Street - Fri Oct 31, 9:36AM CDT
Shares of Mercadolibre (MELI) are up after reporting third quarter earnings per share of 76 cents after the bell Thursday, up from 66 cents a year ago.
MELI: 136.50 (+1.75)

Premarket Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Oct 31, 8:06AM CDT

ANV: 1.08 (+0.03), GPRO: 76.15 (-2.91), MCHP: 43.44 (+0.30), SSRI: 4.80 (-0.40), CDTI: 2.69 (+0.19), IAG: 1.89 (-0.07), AEGR: 21.57 (-0.01), BSBR: 5.54 (+0.01), MUX: 1.24 (-0.17), PT: 1.63 (+0.11), TSU: 25.49 (-0.43), AG: 4.99 (-0.34), TRMB: 27.73 (+0.42), LNKD: 228.90 (+5.86), COMM: 20.86 (-1.73), EGO: 5.32 (-0.32), SRPT: 15.88 (-0.24), BBSI: 24.37 (-0.86), NGD: 3.66 (-0.23), IBIO: 1.24 (+0.08), MELI: 136.50 (+1.75), GRPN: 7.49 (-0.01), IMPV: 43.09 (+0.56)

MercadoLibre Inc. (MELI) Stock Research Links

MELI Board Company Profile Buy Rating Time & Sales News Filings Financials

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Surfing Dogs Ride Waves, Support Orphan Pets

Waves, Paws, and Passion Who would've thought that dogs catching waves could also catch hearts and wallets? Well, that's exactly what's happening today at Del Mar Dog Beach with the 21st Annual Surf Dog Surf-A-Thon revving up the excitement. It's a sun-soaked day in Rancho Santa Fe, California, right in the thick of things at the longest-running dog surf competition. For...

PANDAG G1 Debuts: Revolutionizing Lawn Care Efficiency

The Future of Landscaping Unveiled Get this—PANDAG is set to shake things up at GaLaBau 2026 with their futuristic G1 autonomous mower. This isn't just another piece of lawn equipment; it's practically a tech marvel on wheels, weaving together LiDAR, AI Vision, RTK, and 4G tech to make it the ultimate multitasker for the landscaping industry. We're talking obstacle...

MRI Surveillance Gains Ground in Lung Cancer Care

Shifting the Standard: MRI's Rise in SCLC Treatment Here's a twist that baffles the traditionalists—ditch the prophylactic cranial irradiation (PCI) and catch clearer days with MRI surveillance for small-cell lung cancer (SCLC). The latest international phase III MAVERICK trial might just redraw the lines on what's considered standard care in this relentless disease....

Ris-Rez May Set New Standard in Relapsed SCLC

The Game-Changing Results Innovation in pharmaceuticals sometimes feels like a waiting game, but when a fresh breakthrough like this rolls in, it lights up the whole landscape. Risvutatug rezetecan, or Ris-Rez for short, has shown promising potential in the fight against relapsed small-cell lung cancer (SCLC) that has progressed after platinum-based therapy. Survival...

Tam-Peli Steps Up in SCLC Battle: Trial Insights

Noteworthy Developments in Small-Cell Lung Cancer Treatment Let's dive into a story straight from the world of small-cell lung cancer (SCLC) that doesn't take any prisoners. The antidote making waves is tambotatug pelitecan, or Tam-Peli for short, showcasing its might in the unrelenting fight against relapsed SCLC. The phase III TAISHAN-302 trial puts Tam-Peli...

GORGIE Unleashes Berry Burst: Target's New Drink Star

GORGIE Targets Taste Buds with Berry Burst Ever feel like you're missing out on that energy drink everyone seems to be raving about? Well, GORGIE's out there making some noise again, and this time it's got a new punchy player in the game: Berry Burst. It's not just another drink; it's shaking things up in the energy aisle with its exclusive launch at Target. Modern style...

First-Time Homeowners: Unseen Pitfalls of Insurance

Understanding Homeowners Insurance: Beyond the Basics Most folks diving into homeownership for the first time get caught up in the whirlwind of price tags, loans, and knick-knacks for their new place. Meanwhile, the nitty-gritty of homeowners insurance often gets tossed to the side. But take it from a weary watchdog of financial storms—it’s those details in the policy...

UWM Faces Class Action Deadline: Key Insights for Investors

The High Stakes Reality for UWM Investors If there's one thing that's certain in this jittery world of investing, it's that losses have a way of waking you up. Right now, anyone tied up with UWM Holdings Corporation (NYSE: UWMC) shares needs to keep their wits about them; we're barreling toward an October 13, 2026 deadline for a class action lawsuit. The clock's ticking...

Trial Disappointment: No Significant Gains in NSCLC

Dissecting the Nuances of the EVOKE-03/KEYNOTE-D46 Trial Every once in a while, we come across a trial that rattles cages in the research community. Today, it's the EVOKE-03/KEYNOTE-D46 trial, a collision of hope and hard-knock reality. This Phase 3 trial, which sought to explore the potential combo of sacituzumab govitecan (SG) and pembrolizumab on metastatic non-small...

Regeneron Faces Legal Heat: Lead Plaintiff Deadline Looms

Regeneron’s Tight Spot: Legal Showdown Well, here we go again—Regeneron Pharmaceuticals (NASDAQ:REGN) is under some serious heat. If you're an investor who faced significant losses with this biotech juggernaut, remember that the clock’s ticking down to the wire. By tomorrow, September 14, 2026, you need to decide if you're going to throw your hat in the ring for...